BioNTech starts clinical trial for new omicron-based vaccine

BioNTech and Pfizer have begun a clinical trial to evaluate their latest vaccine for COVID-19. The study will compare the current Pfizer-BioNTech mRNA vaccine with one based on the Omicron variant.

Forscherin arbeitet im Labor
© AlexRaths

The two companies have announced they are evaluating the safety, tolerability, and immunogenicity of an Omicron-based candidate in healthy adults 18 through 55 years of age. There will be three groups in the study, which will look at different regimens of the current Pfizer-BioNTech COVID-19 productand an Omicron-based vaccine.

The CEO and co-founder of BioNTech, Ugur Sahin said, “Vaccines continue to offer strong protection against severe disease caused by Omicron. Yet emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains. This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but with longer duration of protection.”

The study will evaluate 1420 subjects in three groups. In the first, around 600 participants will have already received two doses of the current Pfizer-BioNTech C-19 vaccine and will receive one or two shots of the Omicron-based vaccine. The second group of 600 subjects will have already had three doses of the current vaccine and will get one jab of the omicron-based vaccine. And finally, the third group’s participants will all be initially unvaccinated and receive three doses of the Omicron-based preparation.

The two companies announced in mid-January that they had already begun to produce the Omicron-based candidate vaccine. At that time, Sahin said “We expect that we will be able to supply the market in March if official approval has been issued.” Pfizer CEO Albert Bourla said in an interview that the companies had started to produce the new vaccine at their own risk. He added that it was unclear if the drug would be needed or how it would be used, “but we will be ready.”

The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. HEALTH MADE IN GERMANY is the place to learn more about these innovations and other state-of-the-art-technologies from the country’s medical biotech sector.